CN102008482A - Compound preparation containing valsartan for treating hypertension - Google Patents
Compound preparation containing valsartan for treating hypertension Download PDFInfo
- Publication number
- CN102008482A CN102008482A CN 201010231009 CN201010231009A CN102008482A CN 102008482 A CN102008482 A CN 102008482A CN 201010231009 CN201010231009 CN 201010231009 CN 201010231009 A CN201010231009 A CN 201010231009A CN 102008482 A CN102008482 A CN 102008482A
- Authority
- CN
- China
- Prior art keywords
- levamlodipine
- valsartan
- compound preparation
- blood pressure
- hydrochlorothiazide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound preparation containing valsartan for treating hypertension, which is prepared by mixing levamlodipine or pharmaceutical salts of the levamlodipine, hydrochlorothiazide and valsartan or pharmaceutical salts of the valsartan as main components with a pharmaceutical vector, wherein the levamlodipine or pharmaceutical salts of the levamlodipine are allocated in each preparation unit. The invention has the advantages of an action mechanism of supplementing medicaments can be fully played according to combined drugs, the curative effect of the drug can be improved and the drug quickly reaches the standard, so that the attainment rate of blood pressure reaches 80 percent, which benefits the reduction of adverse effects relevant with the increase of certain dose and maintains longer acting time. The compound preparation has the characteristics of quick response, high attainment rate of blood pressure, small side effect and low cost.
Description
Technical field:
The present invention relates to a kind of compound preparation that hypertension contains valsartan for the treatment of, belong to drug world.
Background technology:
Along with China's rapid growth of economy, the drastic change of people life style, the acceleration of urbanization, aging, the cardiovascular diseases has become first or second cause of the death of rural and urban population.Especially patients with hypertension, its sickness rate accounts for total population about 15%.Morbidity colony is so big, seeks medicine evident in efficacy, that side effect is little and seems more important.
The hypertensive medicine of treatment has multiple at present, such as calcium antagonist (CCBs), converting enzyme inhibitor (ACEI), Angiotensin (ARBs) etc., but single medicine treatment hypertension is difficult up to standard in a short time, and Most patients need be taken two or more antihypertensive drug can reach the blood pressure lowering target.Especially blood pressure exceeds desired value 20/10mmHg, and beginning need be taken two kinds of medicines often.Single medicine is prone to drug resistance, and because the bigger probability that toxicity occurs of dosage is also bigger.Majority is to give two or more drug administration treatments simultaneously.But several drugs is taken simultaneously, and patient's compliance is poor, and the collocation of the dosage of several drugs is not because the problem of formulation dosage and doctor's the degree of awareness often are optimized proportionings.In recent years, though the depressor of much new good effect few side effects is arranged, the controlling blood pressure compliance rate is relatively low.But drug combination can be used two or more depressor, and the dosage of every kind of medicine is little, and the therapeutical effect of medicine should have collaborative or the effect of addition at least, and its ill effect can be cancelled out each other or not overlapping at least or addition.Medicine kind number used during drug combination is too much unsuitable, and crossing to have complicated drug interaction at most.Therefore, select to merge very difficulty of medication amount and kind, need a large amount of development tests.
Therefore, a kind of new treatment pattern is applied to clinical gradually, and the compound hypertension medicine preparation is internationally recognized a kind of orientation treatment.Because the compound antihypertensive drug prescription is followed the principle that different mechanism of action medicines carry out proportioning usually, therefore show as the advantage that increases curative effect or reduce side effect, obtained better controlling of blood pressure effect.
Summary of the invention:
The object of the present invention is to provide a kind of side effect little, taking convenience can effectively be treated the compound preparation of hypertensive three kinds of antihypertensive drugs, and this compound preparation is controlling blood pressure effectively.
Purpose of the present invention is implemented by following technical scheme: a kind ofly treat the compound preparation that hypertension contains valsartan, include following composition: Levamlodipine (Levamlodipine) or Levamlodipine officinal salt, hydrochlorothiazide (hydrochlorothiazide), valsartan (valasartan) or its officinal salt are Main Ingredients and Appearance, being equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described Levamlodipine (Levamlodipine) or Levamlodipine officinal salt, count 2.5-10.0mg with Levamlodipine, described valsartan (valasartan) or its officinal salt, count 20.0-160.0mg with valsartan, described hydrochlorothiazide (hydrochlorothiazide) is 6.25-25.0mg.
It is a kind of that to treat the compound preparation that hypertension contains valsartan be capsule, soft capsule, granule, tablet, powder, controlled release agent or injection dosage form.
Advantage of the present invention: be to give full play to the complementary mechanism of action of medicine according to drug combination to increase curative effect, up to standard fast, make the blood pressure compliance rate reach 80%, reduce with a certain dosage and increase relevant untoward reaction.Compound formulation of the present invention has instant effect, blood pressure compliance rate height, and side effect is little, the characteristics that cost is low.
The specific embodiment:
Further set forth medicine of the present invention by the following examples, these embodiment are only presented for purposes of illustration, do not limit the scope of the invention.
Embodiment 1-4 is listed as follows:
Use the conventional method in the pharmaceuticals industry among the embodiment, the according to the form below formulation becomes tablet, makes the used pharmaceutically suitable carrier of tablet--and adjuvant is the conventional adjuvant of this area.Wherein the proportioning of its Main Ingredients and Appearance is as follows:
| Embodiment | Count (mg/ sheet) with Levamlodipine | Count (mg/ sheet) with valsartan | Hydrochlorothiazide (mg/ sheet) |
| 1 | Levamlodipine 2.5 | Valsartan 20 | Hydrochlorothiazide 6.25 |
| 2 | Levamlodipine 2.5 | Valsartan 160.0 | Hydrochlorothiazide 25.0 |
| 3 | Levamlodipine 5.0 | Valsartan 80 | Hydrochlorothiazide 12.5 |
| 4 | Levamlodipine 10.0 | Valsartan 40.0 | Hydrochlorothiazide 12.5 |
Use the conventional method in the pharmaceuticals industry simultaneously among the embodiment, can also be prepared into capsule, soft capsule, granule, powder, controlled release agent or injection dosage form,, pharmaceutically suitable carrier--used adjuvant is the conventional adjuvant of this area of this dosage form.
Embodiment 5: the present invention treats hypertensive compound preparation clinical trial:
Below will be by human body pharmacodynamic experiment explanation pharmaceutical composition of the present invention to hypertensive therapeutical effect.
1, physical data:
Clinical 400 routine hypertension philtrums, age 40--50 year, 140 examples; Age 51--60 year, 140 examples, age 61--70 year, 120 examples.
2, diagnostic criteria: according to " Chinese hypertension prevention and control guide ", hypertension is defined as: do not obey under the antihypertensive situation systolic pressure 〉=140mmHg and/or diastolic pressure 〉=90mmHg.
3, Therapeutic Method:, adopt randomized to be divided into 4 groups, every group of this compound formulation medicine that adopts embodiment of the invention 1-4 gained respectively with 400 routine hypertensive patients, make tablet, every day is once oral, according to the dose difference of tablet, each a slice or two took 6 days.
4, efficacy assessment standard:
Draft according to " Chinese hypertension prevention and control guide ".The target of antihypertensive therapy is blood pressure to be returned to " normally " or " ideal " level.40-60 year patient be depressurized to ideal or normal arterial pressure (≤130/85mmHg), 60-70 year patient be depressurized at least normal high value (≤140/90mmHg).
5, therapeutic outcome: administration begins to carry out respectively in the 1st day, 2 days, 3 days, 4 days, 5 days, 6 days blood pressure determination.The result shows that medication is after 6 days, 4 groups of the embodiment of the invention are totally 400 routine hypertension philtrums, and it is up to standard to amount to 320 routine patient's blood pressures, promptly returns to " normally " or " ideal " level, mean blood pressure compliance rate 80% illustrates that the present embodiment compound medicine has good curing hypertension effect.
Curative effect sees the following form:
| Case load | Blood pressure case sum up to standard | The below standard case sum of blood pressure | The mean blood pressure compliance rate |
| 400 | 320 | 80 | 80％ |
Discuss
This product is the hypertensive compound formulation of treatment, its blood pressure compliance rate higher 80%.
Claims (2)
1. treat the compound preparation that hypertension contains valsartan for one kind, it is characterized in that, it includes following composition: Levamlodipine or Levamlodipine officinal salt, hydrochlorothiazide, valsartan or its officinal salt be Main Ingredients and Appearance, be equipped with pharmaceutically suitable carrier forms, in wherein every preparation unit, described Levamlodipine or Levamlodipine officinal salt, count 2.5-10.0mg with Levamlodipine, described valsartan or its officinal salt, count 20.0-160.0mg with valsartan, described hydrochlorothiazide is 6.25-25.0mg.
2. a kind of hypertensive compound preparation that comprises valsartan for the treatment of according to claim 1 and 2 is characterized in that described compound preparation is capsule, soft capsule, granule, tablet, powder, controlled release agent or injection dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010231009 CN102008482A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing valsartan for treating hypertension |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910139980.2 | 2009-07-11 | ||
| CN200910139980 | 2009-07-11 | ||
| CN 201010231009 CN102008482A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing valsartan for treating hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102008482A true CN102008482A (en) | 2011-04-13 |
Family
ID=43838951
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010231025 Pending CN102008483A (en) | 2009-07-11 | 2010-07-08 | Candesartan-containing compound preparation for treating hypertension |
| CN 201010231105 Pending CN102008486A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing telmisartan for treating hypertension |
| CN 201010231028 Pending CN102008484A (en) | 2009-07-11 | 2010-07-08 | Olmesartan-containing compound preparation for treating hypertension |
| CN 201010231009 Pending CN102008482A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing valsartan for treating hypertension |
| CN 201010230997 Pending CN102008480A (en) | 2009-07-11 | 2010-07-08 | Irbesartan-containing composite preparation for treating hypertension |
| CN 201010231001 Pending CN102008481A (en) | 2009-07-11 | 2010-07-08 | Eprosartan-containing compound preparation for treating hypertension |
| CN 201010231095 Pending CN102008485A (en) | 2009-07-11 | 2010-07-08 | Losartan-containing compound preparation for treating hypertension |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010231025 Pending CN102008483A (en) | 2009-07-11 | 2010-07-08 | Candesartan-containing compound preparation for treating hypertension |
| CN 201010231105 Pending CN102008486A (en) | 2009-07-11 | 2010-07-08 | Compound preparation containing telmisartan for treating hypertension |
| CN 201010231028 Pending CN102008484A (en) | 2009-07-11 | 2010-07-08 | Olmesartan-containing compound preparation for treating hypertension |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010230997 Pending CN102008480A (en) | 2009-07-11 | 2010-07-08 | Irbesartan-containing composite preparation for treating hypertension |
| CN 201010231001 Pending CN102008481A (en) | 2009-07-11 | 2010-07-08 | Eprosartan-containing compound preparation for treating hypertension |
| CN 201010231095 Pending CN102008485A (en) | 2009-07-11 | 2010-07-08 | Losartan-containing compound preparation for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (7) | CN102008483A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335176A (en) * | 2011-07-14 | 2012-02-01 | 海南锦瑞制药股份有限公司 | Brand-new oral solid medicinal composition and preparation method thereof |
| CN102657657A (en) * | 2012-04-17 | 2012-09-12 | 北京哈三联科技股份有限公司 | Capsule containing valsartan, amlodipine and hydrochlorothiazide |
| CN103479643A (en) * | 2013-10-10 | 2014-01-01 | 沈阳药科大学 | Preparation method of compound preparation for treating high blood pressure |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335177B (en) * | 2011-07-14 | 2013-05-01 | 海南锦瑞制药股份有限公司 | Brand-new oral solid pharmaceutical composition and preparation method thereof |
| CN102335178B (en) * | 2011-07-14 | 2012-12-26 | 海南锦瑞制药股份有限公司 | Oral solid pharmaceutical composition and preparation method thereof |
| CN102327272B (en) * | 2011-07-14 | 2013-08-14 | 海南锦瑞制药股份有限公司 | Oral solid pharmaceutical composition and preparation method thereof |
| CN102342943B (en) * | 2011-07-14 | 2013-07-10 | 海南锦瑞制药股份有限公司 | Brand new oral solid medicinal composition and its preparation method |
| CN102342942B (en) * | 2011-07-14 | 2016-08-31 | 海南锦瑞制药有限公司 | A kind of New oral solid medicinal compositions and preparation method thereof |
| US10390016B2 (en) | 2011-11-04 | 2019-08-20 | Infobridge Pte. Ltd. | Apparatus of encoding an image |
| CN102512691A (en) * | 2012-01-10 | 2012-06-27 | 广州白云山天心制药股份有限公司 | Telmisartan composition and application thereof |
| EP3219309A1 (en) * | 2016-03-17 | 2017-09-20 | K.H.S. Pharma Holding GmbH | Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension |
| CN106389431A (en) * | 2016-11-06 | 2017-02-15 | 成都先先先生物科技有限公司 | Compound pharmaceutical preparation for treating primary hypertension |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
-
2010
- 2010-07-08 CN CN 201010231025 patent/CN102008483A/en active Pending
- 2010-07-08 CN CN 201010231105 patent/CN102008486A/en active Pending
- 2010-07-08 CN CN 201010231028 patent/CN102008484A/en active Pending
- 2010-07-08 CN CN 201010231009 patent/CN102008482A/en active Pending
- 2010-07-08 CN CN 201010230997 patent/CN102008480A/en active Pending
- 2010-07-08 CN CN 201010231001 patent/CN102008481A/en active Pending
- 2010-07-08 CN CN 201010231095 patent/CN102008485A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335176A (en) * | 2011-07-14 | 2012-02-01 | 海南锦瑞制药股份有限公司 | Brand-new oral solid medicinal composition and preparation method thereof |
| CN102657657A (en) * | 2012-04-17 | 2012-09-12 | 北京哈三联科技股份有限公司 | Capsule containing valsartan, amlodipine and hydrochlorothiazide |
| CN103479643A (en) * | 2013-10-10 | 2014-01-01 | 沈阳药科大学 | Preparation method of compound preparation for treating high blood pressure |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102008484A (en) | 2011-04-13 |
| CN102008483A (en) | 2011-04-13 |
| CN102008481A (en) | 2011-04-13 |
| CN102008485A (en) | 2011-04-13 |
| CN102008480A (en) | 2011-04-13 |
| CN102008486A (en) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008482A (en) | Compound preparation containing valsartan for treating hypertension | |
| CN102008711B (en) | Compound preparation containing enalapril for treating hypertension | |
| CN101208097A (en) | Method for the treatment of acne | |
| TW200831078A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| WO2005084392A2 (en) | 4-methylpyrazole formulations for inhibiting ethanol intolerance | |
| CN101966189A (en) | Amlodipine and olmesartan-containing compound preparation for treating hypertension | |
| CN102370730A (en) | Self-heated traditional Chinese medicine (TCM) emplastrum for treating osteoarthritis | |
| CN101966190A (en) | Amlodipine and eprosartan-containing compound preparation for treating hypertension | |
| Rajaram | Review of Captopril Drug Formulation, Mechanism of action, Dosage, Use and Adverse drug reactions | |
| CN101954082A (en) | Angiotensin-converting enzyme inhibitor-containing compound preparation for treating hypertension | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| TW200920371A (en) | A combination treatment | |
| CN101125144A (en) | Compound medicine for treating diabetes | |
| CN101125143A (en) | Hypertension-treating compound medicine | |
| CN113616651B (en) | Compound antihypertensive pharmaceutical composition and application thereof | |
| CN101596203B (en) | Application of syringin in preparing drugs for treating cardiovascular and cerebrovascular diseases | |
| CN117243947A (en) | Application of daphnetin and combination containing daphnetin in preparation of diabetes complication medicaments | |
| CN101940619A (en) | Chinese medicinal preparation for treating guillain-barre syndrome (GBS) diseases and preparation method thereof | |
| CN106265674A (en) | Tetramethyluric acid prevention and the application for the treatment of diabetes | |
| CN114617898A (en) | Compound preparation prepared from clindamycin and cimetidine and preparation method thereof | |
| CN103393682A (en) | Compound medicinal composition of felodipine | |
| CN107648225A (en) | A kind of antihypertensive Western medicine compound and preparation method thereof | |
| CN102743361A (en) | Irbesartan hydrochlorothiazide capsule | |
| CN107648239A (en) | A kind of Western medicine compound for treating hypertension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110413 |